Parkinson Disease Dementia
📧 Sign up to get email alerts when something new happens for Parkinson Disease Dementia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 [Phase 1]
Phase 1 trial update evaluating nilotinib in cognitively impaired Parkinson's disease patients has completed.
-
FDA approval · 2015-11-17FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approves a supplemental application for rivastigmine tartrate submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2015-11-17FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for rivastigmine tartrate from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2015-11-17FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for rivastigmine tartrate submitted by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2015-07-28Clinical Trial Update: Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) [Phase 2]
A Phase 2 trial evaluating memantine for efficacy and safety in dementia associated with Parkinson's disease and dementia with Lewy bodies h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-07-22FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA granted supplemental approval for a generic rivastigmine tartrate product from Dr. Reddy's Laboratories Limited (ANDA 077130).
-
FDA approval · 2015-06-24FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc, indicating an approved change related to this drug. The ac…
-
CLINICAL_TRIALS trial_result · 2015-02-04Clinical Trial Update: An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia
This entry notes the completion of an observational study assessing the prevalence of neuropsychiatric symptoms in Parkinson's Disease Demen…
-
FDA approval · 2015-02-03FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for rivastigmine filed by Sandoz Inc.
-
FDA approval · 2014-08-22FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved rivastigmine tartrate as an original ANDA for Macleods Pharmaceuticals Limited, creating a generic version of rivastigmine tart…
-
CLINICAL_TRIALS trial_result · 2013-09-20Clinical Trial Update: Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies [Phase 4]
Phase 4 study comparing memantine to placebo in Parkinson's disease dementia and dementia with Lewy bodies has completed.
-
FDA approval · 2013-06-27FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2013-05-10Clinical Trial Update: The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia [Phase 3]
A Phase 3 trial evaluating the efficacy, tolerability, and safety of donepezil (Aricept) in patients with Parkinson's disease dementia has c…
-
FDA approval · 2013-03-13FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approves a supplemental application for rivastigmine submitted by Sandoz Inc.
-
FDA approval · 2012-08-31FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2012-07-06Clinical Trial Update: Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
This clinical trial update reports the performance of AclarusDx, a blood-based transcriptomic test for Alzheimer's disease, in US patients n…
-
FDA approval · 2012-06-12FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original application for rivastigmine tartrate as a generic drug. This approval enables a gen…
-
CLINICAL_TRIALS trial_result · 2011-11-28Clinical Trial Update: Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) [Phase 3]
Phase 3 long-term safety data show rivastigmine capsules and patches were generally well tolerated in patients with Parkinson's disease deme…
-
FDA approval · 2010-08-27FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc under NDA022083.
-
FDA approval · 2007-10-31FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Dr. Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories' rivastigmine tartrate as an original-application generic (ANDA) product. It is indicated for the trea…
-
FDA approval · 2007-10-22FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a generic rivastigmine tartrate product from Sun Pharmaceutical Industries under an original ANDA, for the same indications as …
-
FDA approval · 2007-07-06FDA Approved: RIVASTIGMINE — Original Application (Sandoz Inc)
FDA approved rivastigmine under an original application from Sandoz Inc, marking the approval of a rivastigmine generic product.